HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tame metastatic breast cancer
Disease control Recruiting nowThis early-phase study is for people with metastatic HR+ HER2- breast cancer that has spread to the bone. Researchers want to find the best dose of the drug abemaciclib when given together with radiation and hormone therapy. The goal is to control the disease and manage side effe…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:51 UTC
-
New drug XB010 shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. About 396 adults with cancers…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
Can a diabetes drug help breast cancer patients shed pounds and fight recurrence?
Disease control Recruiting nowThis study is testing whether tirzepatide, a drug used for weight loss, can help people with early-stage hormone-positive breast cancer lose at least 5% of their body weight during their regular cancer treatment. About 40 participants will take the drug and be monitored for safet…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
New pill shows promise for Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
New combo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study compares two treatments for advanced estrogen receptor-positive (ER+) breast cancer that has stopped responding to standard therapies. About 297 participants will receive either a combination of elacestrant and capecitabine or capecitabine alone. The goal is to see if …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for advanced breast cancer: experimental drug EP0062 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-/ER+) that has come back or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adu…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for breast cancer patients: drug combo aims to stop recurrence
Disease control Recruiting nowThis study tests whether adding the drug ribociclib to standard hormone therapy can prevent breast cancer from coming back in people whose cancer has already returned in the same area. About 200 adults with hormone receptor-positive, HER2-negative breast cancer will take part. Th…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Oana Danciu • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Blood test may spare thousands of breast cancer patients from chemo
Disease control Recruiting nowThis study is for women with an early, hormone-sensitive type of breast cancer that has a higher chance of coming back. It tests whether a blood test (ctDNA) can identify who can safely skip chemotherapy and instead take a targeted pill (dalpiciclib) plus hormone therapy. About 3…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Can a second targeted drug still work after the first fails? new trial hopes to find out
Disease control Recruiting nowThis study tests whether the drug sacituzumab govitecan (SG) can still shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2 low) who have already received a similar drug called T-DXd. About 75 adults will receive SG at its standard dose. The goal is to …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Reshma L. Mahtani, D.O. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New Triple-Drug combo aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a new drug called VS-6766 combined with two standard drugs (abemaciclib and fulvestrant) in people with advanced HR+/HER2- breast cancer that has spread. The goal is to find the safest dose and see if the combination helps control the cancer. About 63 participant…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New Triple-Drug cocktail aims to control advanced breast cancer
Disease control Recruiting nowThis study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 20 participants will receive the treatment, and researchers will me…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New study aims to find best Pre-Surgery hormone treatment for men with breast cancer
Disease control Recruiting nowThis study is for men with hormone receptor-positive breast cancer that has not yet been removed by surgery. It compares different hormone therapy combinations (tamoxifen, anastrozole, degarelix, and abemaciclib) given before surgery to see which works best. The goal is to improv…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jose Pablo Leone • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New drug cocktail aims to shrink Hard-to-Treat breast tumors
Disease control Recruiting nowThis early-stage study tests a new drug (BGB-21447) combined with standard hormone therapy, with or without another targeted drug, in people with HR+/HER2- breast cancer that has spread. The goal is to find safe doses and see if the combination can shrink tumors. About 120 adults…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Can a vaginal moisturizer ease breast cancer side effects?
Symptom relief Recruiting nowThis study tests whether Revaree Plus, a vaginal moisturizer, can improve vaginal dryness in women with hormone-receptor-positive breast cancer. About 60 participants who have completed primary cancer therapy or are on maintenance treatment will use the product for 8 weeks. The g…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated May 12, 2026 13:39 UTC
-
Blood test may predict when breast cancer drugs fail
Knowledge-focused Recruiting nowThis study is testing a blood test called DiviTum TKa to see if it can spot early signs that hormone-receptor-positive metastatic breast cancer is becoming resistant to treatment. About 100 people starting or changing their hormone therapy or CDK4/6 inhibitor drugs will give bloo…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 16, 2026 23:52 UTC
-
Brain scans may catch silent metastases in advanced breast cancer
Knowledge-focused Recruiting nowThis study looks at whether regular brain MRIs can find cancer that has spread to the brain in people with stage IV breast cancer who have no brain symptoms. About 170 participants will get a screening brain MRI at the start and again at 6 months or when their cancer first progre…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC
-
Gut bugs may hold key to cancer Drug's nasty side effect
Knowledge-focused Recruiting nowThis study looks at why some breast cancer patients get diarrhea from the drug Abemaciclib while others don't. Researchers will compare the gut bacteria of 60 women who are already taking the drug. The goal is to find if certain bacteria protect against diarrhea, which could lead…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Hubei Cancer Hospital • Aim: Knowledge-focused
Last updated May 04, 2026 16:18 UTC